Sunday 9 February 2014


         

Curriculum Vitae

 

Jan Rijn Zeevaart

 


798 Fauna Road.                                             NECSA (Building 1600)

Florauna                                                          PO Box 582

0182                                                                Pretoria

South Africa                                                   0001

+27 (0)84 754 7834                                        + 27 (0)12 305 5786

 

Educational qualifications

 

School                                                 :           Matriculated from Hoërskool Noord-Oosrand

University                                           :           University of Pretoria

Year                                                    :           1991-1994

Degrees obtained                                :           BSc (with distinction), 1993

                                                            :           BSc(Honours) in Chemistry with distinction, 1994

(Part time while employed at NECSA)

University                                           :           University of Cape Town

                                                            :           MSc in Chemistry, 1997

University                                           :           Delft University of Technology (The Netherlands)

                                                            :           PhD, 2001

 

 

EANM Postgraduate Diploma for Radiopharmaceutical Chemistry / Radiopharmacy:

 

·         Module III: CEA/INSTN, Saclay, France, 2009

 

 

Prizes received

 

Departmental Chemistry prize
:
Various prizes as best undergraduate Chemistry student
The SACI James Moir Medal
:
Best performance in Chemistry at honours level if graduated with distinction. 1994
Young Investigator Travel Award to attend the12th International Congress of Radiation Research
 
:
Award to travel to the conference for investigators
within in 5 years of reward of last degree
August 17 – 22, 2003 Brisbane, Australia
The SACI Raikes Medal 2007
:
Chemical researcher in South Africa under the age of 35 whose original chemical research shows outstanding promise

 

 

NRF Rating                                       :           C3 (2008-2014)


 

 

Employment


 

NECSA                                               :           1995 –

South African Nuclear Energy

Corporation (previously AEC of SA)

 

Current position                                  :           Head of Radiochemistry

Scope of work:            Institutional     :           Development of new radiopharmaceutials used in the

treatment of secondary bone metastasis

                                    Commercial     :           Development of isotope production methods to exploit the                                                              use of the SAFARI-I research reactor for commercial ends

North West University (CARST)       :           Extraordinary Associate Professor (2006-2010)

North West University                        :           Extraordinary Associate Professor (2011-2013)

(Drug Research and Development)

 

Publications (39 of which 36 in ISI accredited journals), books (1) and chapters in books (4)

 

>50 conference publications 8 Invited lectures of which 4 where plenary/keynote lectures



 

J.R. Zeevaart, N.V. Jarvis, I. Cukrowski and G.E. Jackson. Blood plasma modelling of the in vivo behaviour of bisphosphonate-metal-ion complexes as radiopharmaceuticals. S. Afr. J. Chem., 1997, 50, 189-194.

Citations: 18                                                   Impact factor: 0.567

 

I. Cukrowski, J.R. Zeevaart and N.V. Jarvis. A potentiometric and differential pulse polarographic study of CdII with 1-hydroxyethylenediphosphonic acid. Anal. Chim. Acta, 1999, 379, 217-226.

Citations: 21                                                   Impact factor: 4.114

 

J.R. Zeevaart, N.V. Jarvis, W.K.A. Louw, G.E. Jackson and R Mouton. Metal-ion speciation in blood plasma incorporating the biphosphonate, 1-hydroxy-4-aminopropilydenediphosphonate (APD), in therapeutic radiopharmaceuticals. J. Inorg. Biochem., 1999, 73, 265-272.

Cited by KH Thompson & C Orvig in Boon and Bane of Metal ions in Medicine, Science 2003, 300 , 936-939 (IR Zeevaart and not JR Zeevaart)

Citations: 35                                                   Impact factor: 3.495

 

J.R. Zeevaart, W.K.A. Louw, N.V. Jarvis, J.M. Wagener, I.C. Dormehl and R.J. Milner. Comparison between blood plasma models (ECCLES) for 153Sm and 166Ho complexed to diphosphonate ligands (possible radiotherapeutic bone agents) and their in vivo behaviour as studied in non-human primates. Isotope Production and Applications in the 21st Century, N.R. Stevenson, World Scientific, 2000, 403-406, ISBN:981-02-4200-x.

Citations: 0                                                     Chapter in book

 

J.R. Zeevaart, N.V. Jarvis, W.K.A. Louw and G.E. Jackson. Metal-ion speciation in blood plasma incorporating the tetraphosphonate, N, N,-dimethylenephosphonate-1-hydroxy-4-aminopropily-denediphosphonate (APDDMP), in therapeutic radiopharmaceuticals. J. Inorg. Biochem., 2001, 83, 57-65.

Citations: 27                                                   Impact factor: 3.495

 

J.R. Zeevaart, W.K.A. Louw, N.V. Jarvis and J.M. Wagener. Comparison of the predicted behaviour of 153Sm, 166Ho and 117mSn containing bone agents, employing blood plasma models (ECCLES), with in vivo results as studied in animals. J. Lab. Comp. Radiopharm., 2001, 44, suppl 1, S799-S801.

Citations: 1                                                     Impact factor: 0.913

 

J.R. Zeevaart, Metal-ion speciation in blood plasma as a tool in predicting the in vivo behaviour of potential bone-seeking radiopharmaceuticals. PhD Thesis, Delft University Press, 2001, ISBN 90-407-2242-0. Nr of pages 163

Citations: 4                                                     Book  

 

N.V. Jarvis, J.R. Zeevaart, J.M. Wagener, W.K.A. Louw, I.C. Dormehl, R.J. Milner and E. Killian. Metal-ion speciation in blood plasma incorporating the water-soluble polymer, polyethyleneimine functionalised with methylene-phosphonate groups, in therapeutic radiopharmaceuticals. Radiochimica Acta, 2002, 12, 237-246.

Citations: 5                                                     Impact factor: 1.459

 

J.R. Zeevaart, W.K.A. Louw, N.V. Jarvis, J.M. Wagener, Z.I. Kolar and R.A.M.J. Claessens. Speciation studies of SnII in blood plasma incorporating proposed bone-seeking ligands as potential therapeutic radiopharmaceuticals. Journal of Radioanalytical and Nuclear Chemistry, 2003, 257, 83-91.

Citations: 11                                                   Impact factor: 1.52

 

J.R. Zeevaart, W.K.A. Louw, Z.I. Kolar, E. Kilian, F.E. Jansen van Rensburg, I.C. Dormehl. Biodistribution and pharmacokinetics of variously molecular sized 117mSn(II)-polyethyleneiminomethyl phosphonate (PEI-MP) complexes in the normal primate model as a potential selective therapeutic bone agent. Arzneimittel-Forschung/Drug Research, 2004, 54, 340-347.

Citations: 12                                                   Impact factor: 0.632

 

T.E. Nomkoko, G.E. Jackson, B.S. Nakani,  W. K. A. Louw, J.R. Zeevaart. Thermodynamic and biodistribution studies of Zn(II), Ca(II),Gd(III) and Cu(II) complexes of 3,3,9,9-tetramethyl-4,8-diazaundecane-2,10-dione dioxime. J. Chem. Soc. Dalton, 2004, 741-749.

Citations: 3                                                     Impact factor: 3.838

 

J.R. Zeevaart, D.R. Jansen, M.F. Botelho, A. Abrunhosa, C. Gomes, L. Metello, Z.I. Kolar, G.C. Krijger, W.K.A. Louw, I.C. Dormehl. Comparison of the predicted in vivo behaviour of the Sn(II)-APDDMP complex and the results as studied in a rodent model. J. Inorg. Biochem. 2004, 98, 1523-1530.

Citations: 6                                                     Impact factor: 3.495

 

I. Cukrowski, D.M. Mogano, J.R. Zeevaart. Voltametry as a virtual potentiometric sensor in modelling of a metal-ligand system and refinement of stability constants. Part 4. An electrochemical study of NiII complexes with methylene disphosphonic acid. J. Inorg. Biochem. 2005, 99, 2308-2321.

Citations: 6                                                     Impact factor: 3.495

 

J.R. Zeevaart, S.A. Shady, A. Goede, M.M. Phetoe, Determination of adsorption characteristics for different Cs selective resins, Proceedings of the 5th International Conference on Isotopes, Editors; H. Bonet, B.J. Allen, C. Chemaly, Medimond, 2005, ISBN 88-7587-186-8, 227-230.

Citations: 0                                                     Chapter in book

 

J.R. Zeevaart, S. Olsen. Recent trends in the concept of specific activity: Impact on radiochemical and radiopharmaceutical producers. Applied Radiation and Isotopes, 2006, 64, 812-814.

Citations: 6                                                     Impact factor: 1.202

 

M.F. Botelho, F. Caramelo, C. Gomes, J.R. Zeevaart , W.K.A. Louw , I.C. Dormehl, Z.I. Kolar , G.C. Krijger , R.J. Milner. 117mSn-APDDMP for Osteosarcoma Treatment. Biodistribution and Dosimetric Considerations.   Radioprotecção (Radioprotection - The official journal of the Portuguese Health Physics Society), 2006, vol 2, nr. 8&9 ISSN-0874-7016

Citations: 0                                                     (Non ISI)

 

J. van Rooyen, Z. Szucs, J.R. Zeevaart. A possible in vivo generator 103Pd/103mRh - Recoil considerations. Applied Radiation and Isotopes, October 2008, 66(10), 1346-1349.

Citations: 6                                                     Impact factor: 1.202

 

D. R. Jansen, J. R. Zeevaart, Z. I. Kolar, K. Djanashvili, J.A. Peters, G. C. Krijger. P-31 NMR study of the valence stability of Tin in its 1-hydroxyethylene-diphosponate (HEDP) and N,N’,N’-trimethylenephosphonate-polyethyleneimine (PEI-MP) complexes. Polyhedron, 2008, 27, 1779–1786.

Citations: 6                                                     Impact factor: 2.118

 

J.M. Wagener, M. K. Dithebe, M.D. Mogano, I. Cukrowski, J.R. Zeevaart. Modelling of the blood plasma species of biguanide derivates exhibiting potential as diagnostic radiopharmaceuticals. South African Journal of Chemistry, 2008, 61, 82-92.

Citations: 1                                                     Impact factor: 0.567

 

Z. Szucs , D. Steyn, E. Vermeulen, I.J. Van der Walt, K. Moodley, S. Verryn. J.R. Zeevaart.  Separation of 103Pd from metal Rh by thermal diffusion impossible. 7th International Conference on Nuclear and Radiochemistry. NRC 7. Budapest, Hungary, 24-29 Aug., 2008. Proceedings. CD-ROM 0 (2008)1-1./ 0.000


Citations: 2                                                     Chapter in book                     

 

D. Jansen, J.R. Zeevaart, A. Denkova, Z. Kolar, G Krijger. The Hydroxyapatite Chemisorption of N,N',N'-trimethylenephosphonate-polyethyleneimine (PEI-MP) Combined with Sn2+ or Sn4+. Langmuir 2009, 25, 2790 – 2796.

Citations: 3                                                     Impact factor: 4.186

 

M.J. Nell, J.M. Wagener, J.R. Zeevaart, E. Kilian, M.A. Mamo, M. Layh, M. Coyanis, C.E.J. van Rensburg. The anti-tumour properties and biodistribution (as determined by the radiolablled equivalent) of Au-compounds intended as potential chemotherapeutics Applied Radiation and Isotopes. 2009, 67, 1370–1376.

Citations: 3                                                     Impact factor: 1.202

 

Z. Szucs, J. Van Rooyen, J.R. Zeevaart. Recoil effects on ß-decaying in vivo generators, interpreted for 103Pd/103Rh.  Applied Radiation and Isotopes. 2009, 67, 1401-1404.

Citations: 6                                                     Impact factor: 1.202

 

J.R. Zeevaart, J.M. Wagener, M. Neves, M.C. Costa, C. Rodrigues, M. Dithebe, E. Kilian, I. Cukrowski. 99mTc-labelled biguanide derivatives: chemical speciation modelling thereof and evaluation in vervets; J Radioanal Nucl Chem. 283, 2010, 123-131.

Citations: 2                                                     Impact factor: 1.52

 

D.R. Jansen, G.C. Krijger, J. Wagener, R.M. Senwedi, K. Gabanamotse, M. Kgadiete, Z.I. Kolar, J.R. Zeevaart.  Blood plasma model predictions for the proposed bone-seeking radiopharmaceutical [117Sn]Sn(IV)-N,N,N’-trimethylenephosphonate-poly(ethyleneimine); Journal of Inorganic Biochemistry, 2009, 103,1265-1272.

Citations: 1                                                     Impact factor: 3.495

 

Janine Suthiram, Kanyisa Mhlaba, Jan Rijn Zeevaart, Hendrik G Visser and Andreas Roodt, Tetrathylammonium tricarbonly-chlorido(pyrazine-2-carboxylato-N1, O) – rhenate (I) Acta Cryst E, 2009, E 65, m1395                        Citations: 1                             Impact factor: 0.35

 

Zoltan Szucs, Danie Moolman, Sabine Verryn, Jan Rijn Zeevaart, The metal Rhodium does not have allotropes, Journal of Radioanalytical and Nuclear Chemistry, 284 (1), 2010, 239-243.

Citations: 1                                                     Impact factor: 1.52

Zoltan Szucs, Mike Sathekge, Biljana Marjanovic-Painter, Judith Wagener, Thato Sello, Carl Wagener, Jan Rijn Zeevaart. Synthesis of I-131 Labelled 4-Iodo-Phenyl-Acetic acid Journal of Labelled Compounds and Radiopharmaceuticals, 2010, 54, 54-58.

Citations: 1                                                     Impact factor: 1.24

 

Janine Suthiram, Jan Rijn Zeevaart, Hendrik G Visser and Andreas Roodt, Tetrathylammonium tricarbonly-chlorido(quinoxaline-2-carboxylato-N1, O) – rhenate (I) Acta Cryst E, 2010, E 66. m1042-m1043.

Citations: 0                                                     Impact factor: 0.35

 

MF Botelho, AM Abrantes, JR Zeevaart , DR Jansen, A Turtoi , ZI Kolar,  M Neves, FHA Schneeweiss, GC Krijger, IC Dormehl. Comparison of the Therapeutic Potential of the Polyphosphonate Pei-Mp Labeled with 99mtc, 117msn, 186re and 188re. Acta Médica Portuguesa, II Série, 2010, 23, 313.

Citations: 0                                                     Impact factor: 0.256

 

David R Jansen, Gerard C. Krijger, Zvonimir. I. Kolar, Bernard A. Zonneberg, Jan Rijn Zeevaart Bone targeting in the radiotherapeutic treatment of bone malignancies. Current Drug Discovery Technologies 2010; 7(4): 233-246.

Citations: 11                                                   Impact factor: 4.90

 

Jan Rijn Zeevaart, Zoltan Szucs, Sandor Takacs, Neil V. Jarvis, David. R. Jansen. Recoil and conversion electron considerations of the 166Dyl166Ho in vivo generator. Radiochimica Acta. 2012, 100, 109-113.

Citations: 1                                                     Impact factor: 1.459

 

O.D. Maslov, G. Ya. Starodub, G.K. Vostokin, M.V. Gustova, S.N. Dmitriev, V.N. Shvetsov, S. Takacs, Z. Szucs, D. Jansen, J.R. Zeevaart. The production of 117mSn with high specific activity by cyclotron. Applied Radiation and Isotopes, 2011, 69 (7), 917-1102.

Citations: 2                                                     Impact factor: 1.202

 

Sepini, L., Jarvis, N.V., Jansen, D.R., Zeevaart, J.R. Thermodynamic evaluation of the stability of the bone-seeking radiopharmaceutical [117Lu]Lu(III)-DOTP under simulated blood plasma conditions. Analitica Chimica Acta. 730 (2012) 66– 70 http://dx.doi.org/10.1016/j.aca.2011.10.068

Citations: 0                                                     Impact factor: 4.114

 

Jan Rijn Zeevaart, Zoltan Szucs, Tamsyn Pulker, Thato Sello, Jacqueline Bracher, Mike Sathekge.  Biodistribution and pharmacokinetics of I-131 labelled 4-Iodophenulacetic acid. Current Radiopharmaceuticals. 5 (2012)  356-362 doi: 10.2174/1874212222801184710

Citations: 1                                                     Impact factor: 0.69 (non ISI)

 

Jan Rijn Zeevaart, Zoltan Szucs, Sandor Takacs, Johann van Rooyen, David Jansen. Recoil and conversion electron implications to be taken into account in the design of therapeutic radiopharmaceuticals utilising in vivo generators. Journal of Labelled Compounds and Radiopharmaceuticals, 2012, 55, 115-119

Citations: 0                                                     Impact factor: 1.24

 

B Kweto, DR Groot, J Suthiram, L Stassen, JR Zeevaart. The use of ammonium carbonate as lixiviant in uranium leaching.  ALTA 2012 conference on nickel/cobalt/copper, uranium & gold. 26 May- 2 June 2012, Perth, Australia. Proceeding of Uranium sessions at ALTA 2012, ISBN: 978-0-9871262-4-5, p.139-149

Citations: 0                                                     Chapter in book                     

 

 

Venter, L., Jansen, D., Wagener, J., Fourie, P.B., Zeevaart, J.R.  Characterization of radiolabelled dry powder leucine, a constituent of inhalable capreomycin.  Drug delivery letters. 2 (2012) 155-161

Citations:                                                        Impact factor: new journal non ISI

 

 

Matthew P. Akerman, Orde Q. Munro, Modisenyane Mongane, Johan A. van Staden, William I. D. Rae, Cornelius J. Bester, Biljana Marjanovic-Painter, Zoltan Szucs and Jan Rijn Zeevaart. Schiff base complex: a potential chemotherapeutic Biodistribution (as determined by the radiolabelled equivalent) of a gold(III) bis(pyrrolide-imine). Journal of Labelled Compounds and Radiopharmaceuticals, 56 (2013) 495-503.

Citations: 0                                                     Impact factor: 1.24

 

 

Jan Rijn Zeevaart, Judith Wagener, Biljana Marjanovic-Painter, Mike Sathekge, Nischal Soni, Christa Zinn, Gary Perkins, Suzanne Smith. "Production of high specific activity 195mPt-cisplatinum at Necsa for Phase 0 clinical trials in healthy individual subjects" Journal of Labelled Compounds and Radiopharmaceuticals, 56 (2013) 530–535.

Citations: 0                                                     Impact factor: 1.24

 

 

Thomas Ebenhan, Jan Rijn Zeevaart, Kobus J Venter, Thavendrian Govender, Gert H. Kruger and Mike M. Sathekge. Preclinical Evaluation of a Promising Infection Imaging PET/CT Biomarker: Feasibility Study of 68Ga-labeled UBI29-41-1,4,7-triazacyclononane-1,4,7-triacetic Acid in a New Zealand Rabbit Model. Journal of Nuclear Medicine. Published January 16, 2014 as doi:10.2967/jnumed.113.128397.

Citations: 0                                                     Impact factor: 5.774

 

M Sathekge, J Wagener, S V Smith , N Soni, B Marjanovic-Painter, C Zinn , C Van de Wiele,  Yves D’Asseler, G Perkins, J R Zeevaart "Biodistribution and dosimetry of 195mPt-cisplatin, a single photon emission computed tomography imaging agent in normal volunteers." Nuklearmedizin, (2013) 52, 222-227.

Citations: 0                                                     Impact factor: 1.322

 

Thomas Ebenhan, Nicholas Chadwick, Mike M. Sathekge, Patrick Govender, Thavendran Govender, Hendrik G. Kruger, Biljana Marjanovic-Painter and Jan Rijn Zeevaart. Peptide synthesis, characterization and 68Ga-radiolabeling of NOTA-conjugated ubiquicidin fragments for prospective infection imaging with PET/CT. Nuclear Medicine and Biology. accepted for publication.

Citations: 0                                                     Impact factor: 3.023

 

Frederik H. Kriel, Zoltan Szucs, Johan A. van Staden, Cornelius J. Bester,  Modisenyane Mongane, Sebastiaan Lamprecht, William I. D. Rae, Jan-Rijn Zeevaart. Biodistribution of a potential chemoteraputic, dinuclear bisphosphinogold(I) dithiocarbamate, as determined by its Au-198 radiolabelled analogue. Journal of Radioanalytical and Nuclear Chemistry, submitted for publication.

Citations: 0                                                     Impact factor: 1.467

 

CARBON-14 RADIOLABELLING AND IN VIVO BIODISTRIBUTION OF A POTENTIAL ANTI-TB COMPOUND. Molahlehi S. Sonopo, Kobus Venter, Suzan Winks, Biljana Marjanovic-Painter and Jan Rijn. Zeevaart. Journal of Labelled Compounds and Radiopharmaceuticals, submitted for publication.

Citations: 0                                                     Impact factor: 1.24

 

 

Optimisation of the Necsa in-house 195mPt-cisplatinum synthesis method.Judith Wagener, Biljana Marjanovic-Painter and Jan Rijn. Zeevaart. Confidential report nr. RC-TRAPT195-REP-10001 accepted for publication.

Citations: 0                                                     Internal peer- reviewed report

 


 

Patents

 

DR Jansen, GC Krijger, ZI Kolar, JR Zeevaart. Method of producing Radionuclides. WO2011/111010. Patent granted in toto.

 

JR Zeevaart, XY Mbianda, Z Szucs. Anticancer agent. PCT Patent Application No. WO 2013/005154. Examination successfully completed.

 

JR Zeevaart, AF Grobler. Pharmaceutical composition. South African Provisional Patent Application No. 2013/08240 filled on 4 November 2013.

 

JR Zeevaart, Z Szucs, JM Wagener, A Pillay. A method of producing ethylenedicysteine deoxyglucosamine (ECDG) and its kit formulation. UK provisional patent filed on 2014/02/07

 

JR Zeevaart, C Driver, DR Jansen, R Hunter, I Parker. Bone agent. In process to file a UK provisional patent.

 

JSF Botha, JR Zeevaart. TRANSFER VESSEL FOR USE IN TRANSFERRING PRODUCTS BETWEEN RADIATION CONTAINMENT CHAMBERS In process to file a UK provisional patent.

Student Supervision

 

Student name
Degree
Role
Period
Mildred Dithebe
MSc, NWU
Co-Supervisor
2000-2002
Kenneth Gabanamotse
MSc, NWU
Supervisor
2003-2004
Ratanang Senwedi
MSc, NWU
Supervisor
2004-2005
David Jansen
MSc, UCT
Co-Supervisor
2005-2007
David Jansen
PhD, TU Delft
Supervisor
2007-2011
Njabuliso Dlamini
MSc, UJ
Co-Supervisor
2009-2011
Janine Suthiram
MSc, UFS
Co-Supervisor
2010-2011
Lebogang Sepini
MSc, NWU
Supervisor
2010-2012
Tsekiso Ranqhai
MSc, UJ
Co-Supervisor
2010-2013
Braam Swanepoel
PhD, NWU
Co-Supervisor
2011-2013
Paul Grobler
PhD, NWU
Co-Supervisor
2011-2013
Thomas Ebenhan
Postdoc, UKZN
Supervisor
2010-2012
Molahlehi Sonopo
Postdoc
Supervisor
2011-2013
Adushan Pillay
Postdoc
Supervisor
2012-2014
Nick Chadwick
MSc, UKZN
Co-Supervisor
2010-2013
Cathryn Driver
PhD, UCT
Co-Supervisor
2010-2014
Njabuliso Dlamini
PhD, UJ
Co-Supervisor
2012-
Brenda Mokaleng
PhD, UP
Co-Supervisor
2011-
Isabel Schoeman
MSc, NWU
Supervisor
2011-2013
Jenine Horn
PhD, UFS
Co-Supervisor
2012-
Kefilwe Thoane
MSc, NWU
Supervisor
2011-
Vusy Mandiwana
MSc, NWU
Supervisor
2012-2013
Jolanda Ackerman
PhD, UJ
Co-Supervisor
2013-
Clinton Rambapanasi
PhD, NWU
Co-Supervisor
2013-
Nomasonto Rapulenyane
PhD, UP
Supervisor
2013-
Vusy Mandiwana
PhD, NWU
Supervisor
2014-
Cathryn Driver
Postdoc
Supervisor
2014-
Adele van As
MSc, NWU
Supervisor
2014-

 


 

 Funding applications

 

NRF incentive funding for rated researchers 2011-2014; R40 000 per year. UID: IFR2011032800058

 

2013 NRF Mobility Travel Grant, R45 000 - UID: 82514

2013 NRF RISP programme Sample oxidiser R 1 254 000 - UID: 86070

2013-2015 NRF PDP (PhD) R 200 000/year  - UID: 86131

2013-2015 NRF PDP (PhD) R 200 000/year – UID: 86132

2013-2014 NRF PDP (Postdoc) R 300 000/year – UID: 86134

2012-2014 NRF PDP (Postdoc) R 300 000/year – UID: 80724

2011-2013 NRF PDP (Postdoc) R 300 000/year – UID: 77940

 

2009-2010 SA-Hungary bilateral R138 000 - UID: 68768

 

2007-2009 KISC (‘An in vitro instead of in vivo approach to develop bone-seeking radiopharmaceuticals as carried out in the Netherlands and South Africa: 117mSn(IV)-ligand complexes’) R249 897 - UID: 63754

 

2007 NRF RISP programme; Remote synthesiser and HPLC. R 1 347 000 - UID: 65277

 

2006-2009 NWO Wotro funding from the Netherlands (Mobility for PhD of DR Jansen at TU Delft) 55 000 Euro

 

THRIP acted as industry partner.

 

Prof HG Kruger.  UKZN, Westville campus, Chemistry dept.

Dr Xavier Mbianda. UJ, Doornfontein campus, Chemical Technology dept.

 

 

DST FP6 seed funding


 

Completed research

 

1.A long standing research interest of myself (which stems from my PhD) is to reduce the number of animal experimentation in radiopharmaceutical drug development. This can be achieved by using an in silico rather than in vivo approach through the establishment of models based on lab chemical procedures. This focussed on the development of new bone seeking radiopharmaceuticals. Over the years Ho-166, Sm-153, Lu-177 and Sn-117m have been included in such a model. In the last 8 years the work focussed on Sn-117m and Lu-177. The established models are based on thermodynamic principles (adsorption on hydroxyl apatite through measurement of the Langmuir equations and blood plasma though the measurement of formation constants) as well as lately kinetic principles by the measurement of to formation rates. Together one is able to elucidate the behaviour of the proposed radiopharmaceutical before it is tested. For the Sn(IV) PEI-MP (a phosphonate polymer that will accumulate passively in tumour areas due to its size making it only possible to escape from vasculature in tumorous area where the blood vessels are ruptured – the so called EPR effect ) system 3 papers in high impact journals (Polyhedron, Langmuir and J. Inorg. Biochem) demonstrated that animal studies should not be pursued. Also of note was the paper in Polyhedron which showed that Sn(II) if complexed to a ligand such as a bisphosphonate does not oxidise readily in vivo to Sn(IV) as is generally asumed. All these results were combined in a review paper in the journal Current Drug Discovery Technologies in 2010 Furthermore over this whole period 10 conference presentations of which 5 were recorded in proceedings, were also presented.

2.For Lu-177 a Lu(III) blood plasma model has been recently drafted and validated. It explains the clinical success of Lu-177 EDTMP. The results were published in a high impact journal (Anal Chim Acta) which also indicates that DOTP will be a very suitable replacement for EDTMP. 

3.A similar methodology was used for the first time for new potential Tc-99m based kidney imaging agents although the formation constants for Tc cannot be measured. The formation constants were published in the SA J Chem and the blood plasma model as well as the preclinical work that proved the model to make accurate in vivo predictions was published in the J Radioanal Nucl Chem.  Our thermodynamic approach was then extended to include kinetic results during the investigation of new bidentate ligands for coordination of Tc/Re tricarbonyl cores. This was successfully achieved and two crystal structures were recorded which were published. The kinetic evaluation is still has to be published.

4.Production of Sn-117m which is a short range emitter and therefore ideal for treating bone metastasis has also received attention over the last eight years. Apart from the selective accumulation of PEI-MP it requires high specific activity Sn-117m to ensure enough activity can be administered. One way of doing this is by using carbon to capture recoiling Sn-117m in nuclear reactor.   This was patented in WO2011/111010 that was awarded in toto. Another way to achieve this is by the alpha bombardment of a Cd target which was performed in a collaborative effort with JINR, Dubna, Russia which was published in Appl Rad Isotop.

5.As a scientist that is always looking for new opportunities I started to interact with Prof Mike Sathekge, head of Nucl. Med (University of Pretoria) at the Steve Biko Academic Hospital. It has been a very fruitful collaboration. He suggested that I-131 labelled phenyl acetic acid would be a good anticancer agent. Phenyl acetic acid is a metabolite that is used by cancerous cell at elevated levels. On its own it is in phase 3 clinical trials. An additional I-131 on the molecule would make for an interesting combination therapy which has always been one of my research interests. The radiolabelling was published in J Lab Comp Radiopharm and the preclinical evaluation in xenografted mice was published in Current Radiopharm. Although no unwanted target organs were identified and the drug would potentially be safe for use in humans a low tumour to background ratio of 2 was recorded. The conclusion was unfortunately that compound will not be feasible as radiotherapeutic agent. However this whole exercise taught myself and co-workers involved the principles of xenograft studies.

6.Based on the positive results achieved with PEI-MP and the EPR effect a project was started to exploit the EPR effect using nanoparticles. This is a world first to marry radiopharmacy and nano-particles exploiting the EPR effect to passively accumulate a smart bomb in bone metastasis. To avoid completion of blood plasma metal ions as was explained above and that nano-particles coordinate poorly to metal ions it was opted for covalently bonded radiophosporous. P-32 has a long range which might not be ideal as bone agent as it would cause damage to surrounding bone marrow, however the short range P-33 could act as replacement. At the time P-32 was produced on the Pelindaba site which made the research easy and desirable to provide new markets for the radioisotope. The synthesis was successful and a patent was filled which was successfully examined, WO 2013/005154. This now requires clinical testing and commercial exploitation.

7.Apart from being involved with research that is applied science and aimed at products over the short and medium term there is always the desire to do more fundamental research. This opportunity came after reading on the idea of in vivo generators. The concept has high potential and uses the concept that a short lived daughter can be used in vivo if its longer lived mother nuclide can be allocated in the target organ providing little damage to the rest of the body while localising in the target organ (tumour) whereafter the daughter decays and does the damage to the tumour cell. I have always believed that short range emitters will be the best answer for therapeutic radiopharmaceuticals. Auger emitters are most suitable for this. The isotope that is a very favourable exponent of this is Rh-103m but its half life is 56 min which makes it impossible to locate in the target in time. However Pd-103 can act as the mother nuclide of this in vivo generator. One problem that is recorded in the literature with this concept is that the chelator that holds the mother nuclide may not lose the daughter nuclide upon decay and resulting recoil. For alpha emitters this phenomena is well known. In collaboration with others a universal equitation for all beta/gamma and auger emitters was developed. This was then tested for the in vivo generator Sr/Y-90 which validated our equation and Dy/Ho-166 for which we calculated it should experience no loss from the DOTA chelator. To our surprise 70% recoil was experienced which coincided with the 70% of relaxation which happens via the Auger emission. The latter is responsible for fragmentation of the chelator. This will therefore also happen to the Pd-103/Rh-103m generator. This implies a delocalised chelator for Pd(II) will have to be designed to make it feasible. 4 papers have been published the most important in J Lab Comp Radiopharm in 2012 and this also presented as an invited plenary speaker at ARCEBS 2010

8.Au compounds are a niche research area in SA which is a big gold producer. In this period three compounds which are very toxic in vitro towards cancer cell lines, were radiolabeled with Au-198 and pre-clinically evaluated in rats. In all cases the result was that the compounds have high affinity for liver and/or lung which makes them unsuitable for further evaluation. Although disheartening for the researchers involved this is vital information from a cost perspective. Two papers appeared; in Appl Rad Iso and J Lab Comp Radiopharm.

9.The next step in my growth was clinical evaluation for which a GMP clean room was established upon my initiative. Platinum agents (such as cisplatin) continue to be the main chemotherapeutic agents used in treatment of cancer patients. However the side effects are well known and often patients suffer form to incorrect doses being administered. It is important to optimize the dose given to each patient. After two years and a big team effort Pt-195m-cisplatinum , GMP compliant, was produced and administered to ten healthy volunteers as part of an ethical approved phase 0 clinical trial. The majority of the injected dose was excreted in the urine within 5 h post injection. A wide range of urinary excretion (between the 10 volunteers) was found which demonstrated the potential of Pt-195m-cisplatinum to be used as companion diagnostic to optimise patients dose. These results were published in 2013 in J Lab Comp Radiopharm. and Nuklearmedzine. I was also invited to present the work at the Australian Society of Nuclear Medicine in April 2013.

10.As mentioned SA has a need for new PET tracers. It was therefore decided that the Radiochemistry group (under my guidance) will develop F-18 ethylcholine as prostate cancer imaging agent. After two years and a big team effort a GMP compliant radiotracer was produced for a 50 patients phase 1 clinical trial in prostate cancer patients. This was successfully completed and the radiotracer is now sold to patients by NTP, Necsa’s commercial subsidiary. Publication of the clinical results will follow soon.

11.In 2010 it became very obvious that the increased nr of PET cameras in South Africa were highly underutilized due to the limitations on F-18 production sites. A Ga-68 generator would be the answer in the third world setting. What is also of interest in the third world setting is to selectively detect infection as opposed to inflammation in HIV compromised patients which present themselves with fever of unknown origin. Therefore in collaboration with Prof Mike Sathekge at UP a section of the UBI peptide was evaluated for these purposes. Under my guidance the labelling was achieved and I facilitated PET imaging studies in monkeys and rabbits after hours at UP as SA lacks a microPET camera.   All this hard work paid off and we can proudly state that Ga-68 radiolablled UBI(30-41)-NOTA is the world’s first PET infection imaging agent. Several conference presentations in 2011-2013 were presented as well a high impact paper in J Nucl Med has recently appeared which demonstrated the selective uptake in a rabbit infection/inflammation model. A 4:1 infection over inflammation ratio was achieved.  Several more high impact papers have been submitted and are in the process of review.

Very gratifying results have been achieved. In both the blood plasma modelling it has been shown a number of times that the predictions of the model are confirmed in vivo. The same for the establishment of the universal equation to calculate recoil of in vivo generators. The 2 clinical trials have also been highly successful.


 

Conference Papers

 

J.R. Zeevaart and N.V. Jarvis, Complexation of trivalent lanthanides by three diphosphonate ligands in blood plasma

33rd Convention of the South African Chemical Institute, Cape Town, South Africa 1995.

 

J.R. Zeevaart, N.V. Jarvis, G.E. Jackson and I. Cukrowski. Investigation into the use of 166Ho complexed to diphosphonate ligands as possible radiopharmaceuticals for bone cancer patients.

4th International Symposium on Applied Bio-inorganic Chemistry (4th ISABC), Cape Town, South Africa, 1997.

 

N.V. Jarvis, J.R. Zeevaart, , J.M. Wagener, G.E. Jackson and I. Cukrowski. Blood plasma models (ECCLES) for 153Sm and 166Ho complexed to diphosphonate ligands.

34th Convention of the South African Chemical Institute, Durban, South Africa 1998.

 

J.R. Zeevaart, W.K.A. Louw, N.V. Jarvis, J.M. Wagener, I.C. Dormehl and R.J. Milner. Comparison between blood plasma models (ECCLES) for 153Sm and 166Ho complexed to diphosphonate ligands (possible radiotherapeutic bone agents) and their in vivo behaviour as studied in non-human primates.

3rd International Conference on Isotopes (3ICI), Vancouver, Canada 1999.

 

J.R. Zeevaart, N.V. Jarvis, W.K.A. Louw, J.M. Wagener, I.C. Dormehl and R.J. Milner. Comparison between blood plasma models (ECCLES) for 153Sm and 166Ho complexed to diphosphonate ligands (possible radiotherapeutic bone agents) and their in vivo behaviour as studied in non-human primates.

35th Convention of the South African Chemical Institute (SACI-2000), Potchefstroom, South Africa 2000.

 

J.R. Zeevaart, W.K.A. Louw, N.V. Jarvis and J.M. Wagener. Comparison of the predicted behaviour of 153Sm, 166Ho and 117mSn containing bone agents, employing blood plasma models (ECCLES), with in vivo results as studied in animals.

12th International Symposium on Radiopharmaceutical Chemistry (12thISRC), Interlaken, Switzerland, 2001.

Published in J. Lab. Comp. Radiopharm. 44, suppl. 1, S799-S801, 2001.

 

J.R. Zeevaart, N.V. Jarvis, W.K.A. Louw, J.M. Wagener, Z.I. Kolar, R.A.M.J. Claessens. A thermodynamic approach towards the evaluation and design of bone-seeking radiopharmaceuticals as illustrated for 117mSn(II)-PEI-MP.

4th International Conference on Isotopes (4ICI), Cape Town, South Africa 2002.

 

J.R. Zeevaart, N.V. Jarvis, W.K.A. Louw, J.M. Wagener, Z.I. Kolar, R.A.M.J. Claessens  A thermodynamic approach towards the evaluation and design of bone-seeking radiopharmaceuticals as illustrated for 117mSn(II)-PEI-MP.

SACI 2002, Port Elizabeth, South Africa, 2002.

 

W.K.A. Louw, J.R. Zeevaart, Z.I. Kolar, I.C Dormehl, J.M. Wagener, R. Milner, E. Kilian, F.H.A. Schneeweiss 117mSn and 186Re radiolabelling of polyethyleneiminomethyl phosphonic acid (PEI-MP), apotential selective therapeutic bone tumour seeker.

South African Society of Nuclear Medicine, Stellenbosch, South Africa, 4-7 Dec. 2002.

Published in Nucl. Med. Comm. , 23,  p.1223-1224, 2002.

 

J.R. Zeevaart, W.K.A. Louw, D.R. Jansen, J.M. Wagener, M.F. Botelho, C. Gomes, L. Metello, A. Abrunhosa, Z.I.Kolar, I.C. Dormehl. Comparison of the predicted behaviour of 117mSn-APDDMP and the in vivo results as studied in rats.

SACI Inorganic ’03 conference, Roodevallei, Pretoria, Sout Africa, June 2003.

 

D.R. Jansen, J.R. Zeevaart, W.K.A. Louw, J.M. Wagener Formation constants for the complexation of APDDMP with Sn(II).

SACI Inorganic ’03 conference, Roodevallei, Pretoria, Sout Africa, June 2003.

 

F. Botelho, I. Dormehl, W. Louw, J.R. Zeevaart, C. Gomes, Z. Kolar, A. Abrunhosa, L. Metello, R. Milner, J. de Lima, F. Schneeweiss, Polyethyleneiminomethyl phosphonate (PEI-MP) for selectively targeting bone malignancies,

European Association of Nuclear Medicine, Amsterdam, the Netherlands, 13 – 27 Aug. 2003.

Published in Eur. J. Nucl. Med. Mol Imaging 30, suppl. 2, S338, 2003.

 

J.R. Zeevaart, W. Louw, J.M. Wagener, F. Botelho, C. Gomes, A. Abrunhosa, L. Metello, Z. Kolar, I. Dormehl, Selective tumour localisation of the bone-seeking radiopharmaceutical 117mSn(II)-PEI-MP as studied in osteosarcoma containing mice,

15th International Symposium on Radiopharmaceutical Chemistry, Sydney, Australia, 10-14 Aug. 2003.

Published in J. Lab. Comp. Radiopharm. 46, suppl. 1, S100, 2003

 

J.R. Zeevaart, W. Louw, J.M. Wagener, I. Dormehl, E. Killian. Selective carriers for the conversion electron radionuclides, 117mSn and 195mPt as potential therapeutic bone agents,

12th International Congress on Radiation Research, Brisbane, Australia, 17-21 Aug. 2003.

 

Z.I. Kolar, R.A.M.J. Claessen, J.R. Zeevaart and G.C. Krijger, Interfacial chemistry in aqueous tin-bisphosphonate / hydroxyapatite systems,

17th Conference of the European Colloid & Interface Science Society, Firenze, Italy, 21 -26 Sept. 2003.

 

F.H.A. Schneeweiss, I.C Dormehl, W.K.A. Louw, J.R. Zeevaart, Z.I. Kolar, F. Botelho, J Wagener, R. Milner, A Abrunhosa, C. Gomes, L. Metello, L de Lima, Radioiaktive Markierung von Polyethyleniminomethyl-phosphonsäure (PEI-MP) mit 117mSn und dessen Reaktion mit auf Nacktmäusen transplantierten Osteosarcoma,

7. Jahrestagung der Gesellschaft fur Biologische Strahlenforschung, 31 March – 2 April 2004, Darmstadt, Germany.

Published in Proceedings the of the above, ISBN 3-00-013476-X

 

L. Metello , J.R Zeevaart, W.K.A. Louw, D.R. Jansen, J.M. Wagener, M.F. Botelho, C. Gomes, A. Abrunhosa,  Z.I. Kolar, I.C. Dormehl. In vivo and in vitro biodistribution studies of 117mSn-APDDMP in Wistar rats

12th European Symposium on Radiopharmacy and Radiopharmaceuticals, Sept  9 - 12, 2004 Gdansk, Poland.

 

Zeevaart JR, Louw WKA, Jansen DR, Botelho MF, Gomes C, Metello L, Abrunhosa A, Kolar ZI, Krijger GC, Dormehl IC. Comparison of tumour uptake in different types of osteosarcoma mice as studied with the potential bone-seeking radiopharmaceutical, 117mSn(II)-PEI-MP

INTERNATIONAL CONGRESS OF RADIOPHARMACY & RADIOPHARMACEUTICAL CHEMISTRY, Sept  25-29, 2004 Istanbul, Turkey, Published in World J. Nucl. Med. 3, 237 (2004)

 

J.R. Zeevaart, S.A. Shady, A. Goede, M.M. Phetoe, Determination of adsorption characteristics for different Cs selective resins

 

J.M. Wagener, O. Perera, J.R. Zeevaart; Production of I125-progesterone tracer. (5th International conference on Isotopes. April 25-29, 2005, Brussels,Belguim)

 

J.M. Wagener, J.R. Zeevaart, M. Neves, M.C. Costa, C. Rodrigues, M.K. Dithebe, O. Knoesen and W.K. Louw.  99mTC LABELED BIGUANIDE DERIVATIVES: CHEMICAL SPECIATION MODELLING OF AND EVALUATION IN VERVETS.

16th Int. Sym. on Radiopharmaceutical Chem. in Iowa City, USA, June 24-28, 2005.

Published in J. Lab. Comp. Radiopharm. 48, suppl. 1, S260, 2005.

 

M. F. Botelho, F. Caramelo, C. Gomes, J. R. Zeevaart , W.K.A. Louw , I.C. Dormehl, Z.I. Kolar , G.C. Krijger , R.J. Milner. Biodistribution and Dosimetric Calculations for 117mSn-APDDMP, a Potential Osteosarcoma Treatment Agent.

Primeiras Jornadas Luso Brasileiras de Protecção Contra Radiações e Décimas Primeiras Jornadas Portuguesas de Protecção Contra Radiações (1st Luso-Brasilian Meeting of Protection against Radiation and XI Portuguese Meeting of Protection against Radiation), Lisbon 25 November, 2005.

 

I. Dormehl, W. Louw , J.R. Zeevaart, Z. Kolar,  F. Botelho, J. Wagener,  R. Milner, A. Abrunhosa, C. Gomes, L. Metello, F. Schneeweiss, J. de Lima. 117mSn and 186Re radiolabelling of Polyethyleneiminomethyl phosphonate (PEI-MP), followed by in vivo targeting of induced osteosarcoma in nude mice.

Radioactive isotopes in clinical medicine and research - 27th Int symposium, Bad Gastein, Austria, 11-14 January 2006.

 

L. Metello, M.F. Botelho, J.R. Zeevaart , I.C. Dormehl, W.K.A. Louw , F. Caramelo, C. Gomes, M. Neves, Z.I. Kolar , G.C. Krijger, R.J. Milner, Comparison of the polyphosphonate; PEI-MP labeled with 117mSn and 186Re as potential therapeutic bone agents,

European Symposium on Radiopharmacy and Radiopharmaceuticals, Lucca, Italy, 30 March- 2 April 2006.

Published in Q. J. Nucl. Med. 50 suppl. 1 p 49, 2006

 

F. Botelho, J.R. Zeevaart, .I Dormehl, W. Louw, F. Caramelo, L. Metello, C. Gomes, M. Neves, C. Sena, A.N. Abrantes,  Z. Kolar, G. Krijger,  Dosimetric evaluations of the polyphosphonate; PEI-MP labeled with Sn-117m, Re-186 and Tc-99m as potential  diagnosis/therapeutic bone agents. European Association of Nuclear Medicine, Athens, Greece, the Netherlands, 1-3 October 2006.

Published in Eur. J. Nucl. Med. Mol Imaging 33, suppl. 2, S309, 2006.

 

J.R. Zeevaart, J.M. Wagener, M.J. Nell, E. Kilian, M.A. Mamo, M. Layh, M. Coyanis, C.E.J. van Rensburg; Determination of the biodistribution of Au-compounds (intended as potential chemotherapeutics) by the use of radiolabelled tracers.

2nd CONFERENCE on Imaging in Pre-clinical & Clinical Drug Development , Boston, USA, March 16th and 17th 2007.

 


J.R. Zeevaart,, D.R. Jansen , Z.I. Kolar, J.A. Peters, G.C. Krijger Towards a Radiopharmaceutical for Palliative Treatment of Metastatic Bone Pain: a Novel 117mSn(SnII or SnIV)-Polymer Complex. 17th International Symposium on Radiopharmaceutical Sciences, Aachen, Germany from 30 April – 4 May 2007.

Published in J. Lab. Comp. Radiopharm. 50, suppl. 1, S452, 2007.

 

J.R. Zeevaart , D.R. Jansen,  Z.I. Kolar, J.A. Peters , G.C. Krijger , Progress made with potential 117m Sn [Sn (II)] Radiopharmaceuticals aimed at treating secondary bone metastasis: Clarifying their in vivo oxidation state. INORG 007 conference of the South African Chemical Institute, Club Mykonos, West Coast 8-12 July 2007.

Invited lecture

 

F. Botelho, J.R. Zeevaart, D.R. Jansen, A. Turtio, A.M. Abrantes, Z.I. Kolar, M.A. Neves, F.H.A. Scheneeweiss, G.C. Krijger, I.C. Dormehl.  Comparison of the sizes of the potential therapeutic bone agents, the   polyphosphonate PEI-MP labeled with 117mSn and 186Re Dosimetric evaluations of the polyphosphonate. European Association of Nuclear Medicine, Copenhagen, Denmark, 13-17 October 2007.

Published in Eur. J. Nucl. Med. Mol Imaging  34, suppl. 2, P354, 2007.

 

J.R.Zeevaart , J.M.Wagener , M. Neves , M.C. Costa , C. Rodrigues ,O. Knoesen , M.K. Dithebe , E. Kilian , I. Cukrowski 99m Tc labeled biguanide derivatives:  chemical speciation modeling thereof and evaluation in vervets.

RheManTec International conference 19-24 November 2007 Bloemfontein.

 

D.R. Jansen, J.R. Zeevaart, Z.I. Kolar, K. Djanashvilik, J. A. Peters, G.C. Krijger, Towards understanding the in vivo behaviour of potential (117m sn)sn-based radiopharmaceuticals aimed at treating secondary bone metastasis.

South African Young Nuclear Professional Society:  6 November 2007:  Alpha Conference Centre.

 

J.R. Zeevaart, D.R. Jansen, Z.I. Kolar, G.C. Krijger  Sn-117m PEI-MP (N,N’,N’-trimethylenephosphonate-polyethyleneimine) as potential bone metastasis agent; Adsorption behavior on  hydroxyapatite.

6th International conference on Isotopes, 12-16 May 2008, Seoul, S. Korea.

 

C.C.P. Wagener, J.R. Zeevaart.  The labeling of fluoroquinolones with F-18.

6th International conference on Isotopes, 12-16 May 2008, Seoul, S. Korea.

 

Z. Szucs, J. van Rooyen, J.R. Zeevaart. A possible in vivo generator 103Pd/103mRh - Recoil considerations.

6th International conference on Isotopes, 12-16 May 2008, Seoul, S. Korea.

 

J.M. Wagener, J.R. Zeevaart, M.J. Nell, E. Kilian, M.A. Mamo, M. Layh, M. Coyanis, C.E.J. van Rensburg.  Determination of the biodistribution of Au-compounds (intended as potential chemotherapeutics) by the use of radiolabelled tracers.

6th International conference on Isotopes, 12-16 May 2008, Seoul, S. Korea.

 

S.M Rubow, F. De Klerk, E. Kilian, O. Knoesen, J.M. Wagener, J. Naidoo, J.R. Zeevaart.  EVALUATION OF BIODISTRIBUTION OF Tc-99m IgG FOR INFECTION IMAGING.

SA Society for Nucl. Med. 21-26 August 2008, Society of Nuclear Medicine, Windhoek, Namibia.

 

J. R. Zeevaart, D. R. Jansen, Z. I. Kolar, G. C. Krijger.Sn-117m PEI-MP (N,N’,N’-trimethylenephosphonate-polyethyleneimine) as potential bone metastasis agent; Adsorption behaviour on  hydroxyapatite,; South African Society of Nuclear Medicine, 21-26 August 2008, Windhoek, Namibia.

 

Z. Szucs , D. Steyn,E. Vermeulen, I.J. Van der Walt, K. Moodley, S. Verryn. J.R. Zeevaart.  Separation of 103Pd from metal Rh by thermal diffusion impossible. 4 NRC7 - SEVENTH INTERNATIONAL CONFERENCE ON NUCLEAR AND RADIOCHEMISTRY Budapest, Hungary 24-29 August 2008

 

JR Zeevaart, JM Wagener, J Naidoo, O Knoesen, E Kilian, J Perils, SM Rubow,Technetium in the third world setting.R&D in South Africa.

Int Symposium on Tc and Re, 7-10 Oct 2008, Port Elizabeth, South Africa

Invited Plenary lecture

 

J. Topkin, P. Mitchel,  Z. Szucs, J.R. Zeevaart, New method for preparing 35S in the form as a sulfite to be used as tracer in medical and physiological research Tracer 5, 2-6 November 2008, Tiradentes-MG, Brazil.

 

W.G. Augustyn, J.B. Wagener, J.T. Nel, W. Meyer, J.R. Zeevaart, Z. Szucs, A. Goede. Nano@Necsa;

Nano Afica 2009 International Conference, 1-4 February 2009, CSIR conference centre, Pretoria, South Africa.

 

D.R. Jansen, J.R. Zeevaart, O.D. Maslov, Z.I. Kolar, G.C. Krijger. More with less: Possible methods of producing 117mSn with high specific activity, 18th International Symposium on Radiopharmaceutical Sciences, 12-17 July 2009,Edmonton, Canada.

Published in J. Lab. Comp. Radiopharm. 52, suppl. 1, S452, 2009.

 

N.L. Dlamini, X.Y Mbianda, Z. Szucs, J.R.Zeevaart. Synthesis and characterization of bisphosphonate conjugated carbon nanomaterials as a potential system for the treatment of secondary bone cancer. Biomaterials-Africa 2009 Conference, 20-22 September 2009, Pretoria, South Africa.

 

D.R. Jansen, J.R. Zeevaart, O.D. Maslov, Z.I. Kolar, G.C. Krijger,  More with less: Possible methods of producing 117mSn with high specific activity, 18th International symposium on radiopharmaceutical sciences conference in Edmonton, Canada, 12 – 17 July 2009.

 

J.R. Zeevaart, D.R. Jansen, K Gabanamotse, Z.I. Kolar,  G.C. Krijger, An in vitro instead of in vivo approach to develop 117mSn based bone-seeking radiopharmaceuticals as studied for Sn(II) and Sn(IV) complexes of the polymer polyethyleniminomethyl phosphonic acid(PEI-MP); IAEA Technical Meeting on Therapeutic Radiopharmaceuticals IAEA HQ, Vienna, Austria 16 to 20 November 2009.

 

N.L. Dlamini, X.Y. Mbianda, J.R. Zeevaart, Z. Szucs. Synthesis and characterisation of bisphosphonates conjugated carbon nanotubes conjugates as a potential treatment for secondary bone cancer. “ICS-UNIDO conference on Advanced diagnostics and drug-delivery at the nanoscale: state of the art and possible applications to orphan diseases” 13-15 October 2009. Trieste, Italy.

Published in European Cells and Materials Vol. 19. Suppl. 1, 2010 (page 21) ISSN 1473-2262.

 

J.R. Zeevaart, Z. Szucs, S. Takacs, K Gabanamotse, N.V. Jarvis. In vivo generators – recoil and conversion electrons considerations. RadChem 2010, Marianske Lazne, Czech republic,18-23 April 2010.

Invited lecture

 

J Suthiram, Kanyisa Mhlaba, Jan Rijn Zeevaart, Hendrik G Visser and Andreas Roodt.

International symposium on Technetium and other radiometals in chemistry and medicine, Brixen Bressanone, Italy September 8 – 11, 2010.

 

Z Szucs, M Sathekge, B Marjanovic-Painter, JM Wagener, T Sellot, CCP Wagener, JR Zeevaart. Synthesis and biodistribution of I-131 labelled 4-iodophenyl acetic acid. 10 th Congress of WNFMB, Cape Town South Africa, 18 – 23 September 2010.

Published in World Journal of Nuclear Medicine – Volume 9, September 2010, S169

 

D.R. Jansen, J.R. Zeevaart, O.D. Maslov, Z.I. Kolar, G.C. Krijger  More with less: Possible methods of producing 117mSn with high specific activity

10 th Congress of WNFMB, Cape Town South Africa, 18 – 23 September 2010

Published in World Journal of Nuclear Medicine – Volume 9, September 2010, S41

 

J.R. Zeevaart, Z. Szucs, S. Takacs, DR Jansen, N.V. Jarvis. Recoil and conversion electrons considerations of the 166Dy/166Ho in vivo generator. 2nd International Conference on the Application of Radiotracers in Chemical, Environmental and Biological Sciences (ARCEBS 10) Kolkata, India, 8-13 November 2010.

Invited Plenary lecture

 

T Ebenhan, Z Szucs, K. Cimpeanu, D  Dudu J.R. Zeevaart. Production of 68Ge from natural Zink by cyclotron 1st World Congress on Gallium-68 and Peptide Receptor Radionuclide Therapy (PRRNT) THERANOSTICS – on the Way to Personalized Medicine, Zentralklinik Bad Berka, Germany – June 23-26, 2011.

Published in World Journal of Nuclear Medicine – Volume 10, June 2011, 73

 

T Ebenhan, N. Chadwick, T. Govender, H.G. Kruger, M. Sathekge, J.R. Zeevaart. Gallium-68 labelling of NOTA-peptide conjugates for imaging infection – especially tuberculosis. 1st World Congress on Gallium-68 and Peptide Receptor Radionuclide Therapy (PRRNT) THERANOSTICS – on the Way to Personalized Medicine, Zentralklinik Bad Berka, Germany – June 23-26, 2011.

Published in World Journal of Nuclear Medicine – Volume 10, June 2011, 86

 

David R Jansen, Jan Rijn Zeevaart, Zvonimir I Kolar, Gerard C Krijger. An in vitro approach to evaluate and develop potential 117m Sn based bone-seeking radiopharmaceuticals. 2nd Annual SA Young Scientists Conference, 26 – 27 September 2011, Pretoria, South Africa

 

J Suthiram, HG Visser, JR Zeevaart, A Roodt. Crystallographic and kinetic studies of Re(I)-tricarbonyl complexes with nN,O)-donar bidentate ligands. 2nd Annual SA Young Scientists Conference, 26 – 27 September 2011, Pretoria, South Africa

 

LC Sepini, DR Jansen, NV Jarvis JR Zeevaart. Towards establishing a blood plasma model for Lu(III). 2nd Annual SA Young Scientists Conference, 26 – 27 September 2011, Pretoria, South Africa

 

DR Jansen, LC Sepini, NV Jarvis, JR Zeevaart. Towards establishing a blood plasma model for Lu(III). 7th International Conference on Isotopes, Russia 4-8 September 2011.

 

C Driver, MI Parker, R Hunter, JR Zeevaart, The Development of a Gluco-Albumin Macromolecule as a Specific Targeting Agent for Tumors SANHARP 2nd Annual postgraduate conference Cape Town

12-14 October 2011

 

S.M. Ferreira, A.M. Abrantes, L.F. Metello,  J.R. Zeevaart, W.K.A. Louw, I.C. Dormehl,  M.F. Botelho. 188Re-PEI-MP as a potential agent for metabolic radiotherapy. European Association of Nuclear Medicine, Birmingham, UK, 15-19 October 2011.

Published in Eur. J. Nucl. Med. Mol Imaging  38, suppl. 2, S213, 2011

 

B Kweto, DR Groot, J Suthiram, L Stassen, JR Zeevaart. The use of ammonium carbonate as lixiviant in uranium leaching.  ALTA 2012 conference on nickel/cobalt/copper, uranium & gold. 26 May- 2 June 2012, Perth, Australia

Published in Proceeding of Uranium sessions at ALTA 2012, ISBN: 978-0-9871262-4-5, p.139-149

 

T. Ebenhan T. Govender, G.H. Kruger, T. Pulker, V.Naidoo, J.R. Zeevaart and M. Sathekge. Synthesis of 68Ga-NOTA-UBI30-41 and in vivo Biodistribution in vervet Monkeys towards potential PET/CT Imaging of Infection. SNM 2012 annual meeting, 9-13 June 2012,Miami beach, Florida, USA. Published in J. Nucl. Med. 2012 vol 53, suppl 1, P1520,

 

JR Zeevaart, ‘Radiospoorders – 'n visualiseringstegniek behulpsaam om medisyne(middels) vinniger te ontwikkel’ Simposium 2012 of the ‘Suid Afrikaanse Akademie vir Wetenskap en Kuns’

21-22 June 2012, Pretoria, SA

Invited keynote lecture

 

Wagener J.M., Zinn C., Marjanovic-Painter B., Soni N., Perkins G., Sathekge M.M., Smith S.V, Zeevaart J.R., Production of high specific activity 195mPt-Cisplatinum at Necsa for Phase 0 clinical trial in healthy individuals subjects.  11th International Symposium on the Synthesis and Applications of Isotopes and Isotopically Labelled Compounds (IIS XI), Heidelberg, Germany (9-13 September 2012)

 

Zeevaart J.R, Szucs Z. Takacs S., van Rooyen J. , Jansen D.,  Recoil and conversion electron implications to be taken into account in the design of therapeutic radiopharmaceuticals utilising in vivo generators.  NRC-8, 16-20 September 2012, Como, Italy

Invited lecture

 

Ferreira S., Lranjo M., Abrantes A.M., Brito A.F., Metello L., Zeevaart J.R., Louw W., Dormehl I., Botelho M.F.  A comparative study to analyse the potential of 99mTc-PEI-MP for diagnosis and 188Re-PEI-MP for therapy of bladder carcinoma and osteosarcoma.  5th Annual meeting of the World Molecular Imaging Congress, Dublin Ireland, 5-8 September 2012

 

Ebenhan T., Zeevaart J.R., Govender T., Kruger H.G., Pulker T., Sathekge M.M, Preparation of a promising infection PET/CT imaging biomarker: 68Ga-labeled UBI30-41-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility study in a vervet monkey model.  South African Society of Nuclear Medicine, Parys, South Africa, 21-24 September 2012

 

Wagener J., Zinn C., Marjanovic-PainterB., Soni N., Perkins G. , Sathekge M. , Smith S.V. , Zeevaart J.R., Production of high specific activity 195mPt-Cisplatin at NECSA for Phase 0 clinical trial in healthy individuals subjects.  South African Society of Nuclear Medicine,  Parys, South Africa, 21-24 September 2012.

 

vd Westhuizen D., Wagener C.P., van Otterlo A.L., Sello T.  The construction and configuration of a “homemade” remote synthesis unit for the synthesis of radiolabelled [F-18] Fallypride tracer. South African Society of Nuclear Medicine,Parys, South Africa, 21-24 September 2012.

 

J.R. Zeevaart, Two sides of the radiochemistry coin: Radiopharmaceuticals and Biological Radiotracers. SACI Centenary Lectures, UP, Pretoria, SA, 28 September 2012

Invited keynote lecture & NWU (Mafikeng campus) research day

 

Wagener J.M., Zinn C., Marjanovic-Painter B., Soni N., Perkins G., Sathekge M.M., Smith S.V, Zeevaart J.R., Production of high specific activity 195mPt-Cisplatinum at Necsa for pahse 0 clinical trials in healthy individuals, ANZSNM, Perth Australia, 11 – 15 April 2013

Invited lecture

 

J.R. Zeevaart, Z. Szucs, S. Takacs, DR Jansen. Recoil and conversion electron implications to be taken into account in the design of therapeutic radiopharmaceuticals utilising in vivo generators. ANZSNM, Perth Australia, 11 – 15 April 2013

 

Jansen, David R., Sepini, Lebogang C. Jarvis, Neil V. Zeevaart, Jan Rijn  A thermodynamic evaluation of 1,4,7,10-tetraazacyclododecane-1,4,7,10 tetra(methane-phosphonic acid) (DOTP) as a component of the bone-seeking radiopharmaceutical [177Lu]Lu(ΙII)-DOTP, towards establishing blood plasma model for  Lu(III). 20th International Symposium on Radiopharmaceutical Sciences 2013, IC Jeju, Korea, 12-17 May 2013

Published in J Label Compd Radiopharm 2013; 56: S439

 

Jansen, David R., Sepini, Lebogang C. Jarvis, Neil V. Zeevaart, Jan Rijn  Complexation studies of [177Lu]Lu(ΙII) with ethylenediaminetetra(methylene phosphonic acid) (EDTMP) as a potential agent for bone pain palliative radiotherapy. 20th International Symposium on Radiopharmaceutical Sciences 2013, IC Jeju, Korea, 12-17 May 2013

Published in J Label Compd Radiopharm 2013; 56: S440

 

J R Zeevaart, S Winks, M S Sonopo SYNTHESIS AND CARBON-14 RADIOLABELLING OF A POTENTIAL ANTI-TB COMPOUND International Isotope Society - Central European Division workshop September 26-2,72013 Bad Soden, Germany

 

Thomas Ebenhan1,5, Jacobus D. Venter2, Daniel J. Goosen3, JanRijn Zeevaart4, Neil Jarvis5, Mike Sathekge1 NOTA conjugation to UB129-41 allows highly selective infection imaging with PET/CT:  A feasibility study in rabbits. World molecular Imaging congress, 2013, 18-21 September 2013, Savannah, USA

Published in Molecular Imaging and Biology 2014: 15, S1137-1138

 


 

Publications in proceedings

 

 

J.R. Zeevaart, W.K.A. Louw, N.V. Jarvis, J.M. Wagener, I.C. Dormehl and R.J. Milner. Comparison between blood plasma models (ECCLES) for 153Sm and 166Ho complexed to diphosphonate ligands (possible radiotherapeutic bone agents) and their in vivo behaviour as studied in non-human primates. Published in Isotope Production and Applications in the 21st Century, N.R. Stevenson, World Scientific, 2000, 403-406, ISBN:981-02-4200-x.

 

J.R. Zeevaart, W.K.A. Louw, N.V. Jarvis and J.M. Wagener. Comparison of the predicted behaviour of 153Sm, 166Ho and 117mSn containing bone agents, employing blood plasma models (ECCLES), with in vivo results as studied in animals.

12th International Symposium on Radiopharmaceutical Chemistry (12thISRC), Interlaken, Switzerland, 2001.

Published in J. Lab. Comp. Radiopharm. 44, suppl. 1, S799-S801, 2001.

 

W.K.A. Louw, J.R. Zeevaart, Z.I. Kolar, I.C Dormehl, J.M. Wagener, R. Milner, E. Kilian, F.H.A. Schneeweiss 117mSn and 186Re radiolabelling of polyethyleneiminomethyl phosphonic acid (PEI-MP), apotential selective therapeutic bone tumour seeker.

South African Society of Nuclear Medicine, Stellenbosch, South Africa, 4-7 Dec. 2002.

Published in Nucl. Med. Comm. , 23,  p.1223-1224, 2002.

 

F. Botelho, I. Dormehl, W. Louw, J.R. Zeevaart, C. Gomes, Z. Kolar, A. Abrunhosa, L. Metello, R. Milner, J. de Lima, F. Schneeweiss, Polyethyleneiminomethyl phosphonate (PEI-MP) for selectively targeting bone malignancies,

European Association of Nuclear Medicine, Amsterdam, the Netherlands, 13 – 27 Aug. 2003.

Published in Eur. J. Nucl. Med. Mol Imaging 30, suppl. 2, S338, 2003.

 

J.R. Zeevaart, W. Louw, J.M. Wagener, F. Botelho, C. Gomes, A. Abrunhosa, L. Metello, Z. Kolar, I. Dormehl, Selective tumour localisation of the bone-seeking radiopharmaceutical 117mSn(II)-PEI-MP as studied in osteosarcoma containing mice,

15th International Symposium on Radiopharmaceutical Chemistry, Sydney, Australia, 10-14 Aug. 2003.

Published in J. Lab. Comp. Radiopharm. 46, suppl. 1, S100, 2003

 

F.H.A. Schneeweiss, I.C Dormehl, W.K.A. Louw, J.R. Zeevaart, Z.I. Kolar, F. Botelho, J Wagener, R. Milner, A Abrunhosa, C. Gomes, L. Metello, L de Lima, Radioiaktive Markierung von Polyethyleniminomethyl-phosphonsäure (PEI-MP) mit 117mSn und dessen Reaktion mit auf Nacktmäusen transplantierten Osteosarcoma,

7. Jahrestagung der Gesellschaft fur Biologische Strahlenforschung, 31 March – 2 April 2004, Darmstadt, Germany.

Published in Proceedings the of the above, ISBN 3-00-013476-X

 

Zeevaart JR, Louw WKA, Jansen DR, Botelho MF, Gomes C, Metello L, Abrunhosa A, Kolar ZI, Krijger GC, Dormehl IC. Comparison of tumour uptake in different types of osteosarcoma mice as studied with the potential bone-seeking radiopharmaceutical, 117mSn(II)-PEI-MP

INTERNATIONAL CONGRESS OF RADIOPHARMACY & RADIOPHARMACEUTICAL CHEMISTRY, Sept  25-29, 2004 Istanbul, Turkey, Published in World J. Nucl. Med. 3, 237 (2004)

 

J.M. Wagener, J.R. Zeevaart, M. Neves, M.C. Costa, C. Rodrigues, M.K. Dithebe, O. Knoesen and W.K. Louw.  99mTC LABELED BIGUANIDE DERIVATIVES: CHEMICAL SPECIATION MODELLING OF AND EVALUATION IN VERVETS.

16th Int. Sym. on Radiopharmaceutical Chem. in Iowa City, USA, June 24-28, 2005.

Published in J. Lab. Comp. Radiopharm. 48, suppl. 1, S260, 2005.

 

J.R. Zeevaart, S.A. Shady, A. Goede, M.M. Phetoe, Determination of adsorption characteristics for different Cs selective resins,

Published in Proceedings of the 5th International Conference on Isotopes, Editors; H. Bonet, B.J. Allen, C. Chemaly, Medimond, 2005, ISBN 88-7587-186-8, 227-230.

 

 

L. Metello, M.F. Botelho, J.R. Zeevaart , I.C. Dormehl, W.K.A. Louw , F. Caramelo, C. Gomes, M. Neves, Z.I. Kolar , G.C. Krijger, R.J. Milner, Comparison of the polyphosphonate; PEI-MP labeled with 117mSn and 186Re as potential therapeutic bone agents,

European Symposium on Radiopharmacy and Radiopharmaceuticals, Lucca, Italy, 30 March- 2 April 2006.

Published in Q. J. Nucl. Med. 50 suppl. 1 p 49, 2006

 

F. Botelho, J.R. Zeevaart, .I Dormehl, W. Louw, F. Caramelo, L. Metello, C. Gomes, M. Neves, C. Sena, A.N. Abrantes,  Z. Kolar, G. Krijger,  Dosimetric evaluations of the polyphosphonate; PEI-MP labeled with Sn-117m, Re-186 and Tc-99m as potential  diagnosis/therapeutic bone agents. European Association of Nuclear Medicine, Athens, Greece, the Netherlands, 1-3 October 2006.

Published in Eur. J. Nucl. Med. Mol Imaging 33, suppl. 2, S309, 2006.

 

J.R. Zeevaart,, D.R. Jansen , Z.I. Kolar, J.A. Peters, G.C. Krijger Towards a Radiopharmaceutical for Palliative Treatment of Metastatic Bone Pain: a Novel 117mSn(SnII or SnIV)-Polymer Complex. 17th International Symposium on Radiopharmaceutical Sciences, Aachen, Germany from 30 April – 4 May 2007.

Published in J. Lab. Comp. Radiopharm. 50, suppl. 1, S452, 2007.

 

 

F. Botelho, J.R. Zeevaart, D.R. Jansen, A. Turtio, A.M. Abrantes, Z.I. Kolar, M.A. Neves, F.H.A. Scheneeweiss, G.C. Krijger, I.C. Dormehl.  Comparison of the sizes of the potential therapeutic bone agents, the   polyphosphonate PEI-MP labeled with 117mSn and 186Re Dosimetric evaluations of the polyphosphonate. European Association of Nuclear Medicine, Copenhagen, Denmark, 13-17 October 2007.

Published in Eur. J. Nucl. Med. Mol Imaging  34, suppl. 2, P354, 2007.

 

Z. Szucs , D. Steyn, E. Vermeulen, I.J. Van der Walt, K. Moodley, S. Verryn. J.R. Zeevaart.  Separation of 103Pd from metal Rh by thermal diffusion impossible. 7th International Conference on Nuclear and Radiochemistry. NRC 7. Budapest, Hungary, 24-29 Aug., 2008.

Published in the Proceedings. CD-ROM 0 (2008)1-1./ 0.000

 

N.L. Dlamini, X.Y. Mbianda, J.R. Zeevaart, Z. Szucs. Synthesis and characterisation of bisphosphonates conjugated carbon nanotubes conjugates as a potential treatment for secondary bone cancer. “ICS-UNIDO conference on Advanced diagnostics and drug-delivery at the nanoscale: state of the art and possible applications to orphan diseases” 13-15 October 2009. Trieste, Italy.

Published in European Cells and Materials Vol. 19. Suppl. 1, 2010 (page 21) ISSN 1473-2262.

D.R. Jansen, J.R. Zeevaart, O.D. Maslov, Z.I. Kolar, G.C. Krijger. More with less: Possible methods of producing 117mSn with high specific activity, 18th International Symposium on Radiopharmaceutical Sciences, 12-17 July 2009,Edmonton, Canada.

Published in J. Lab. Comp. Radiopharm. 52, suppl. 1, S452, 2009.

 

 

Z Szucs, M Sathekge, B Marjanovic-Painter, JM Wagener, T Sellot, CCP Wagener, JR Zeevaart. Synthesis and biodistribution of I-131 labelled 4-iodophenyl acetic acid. 10 th Congress of WNFMB, Cape Town South Africa, 18 – 23 September 2010.

Published in World Journal of Nuclear Medicine – Volume 9, September 2010, S169

 

D.R. Jansen, J.R. Zeevaart, O.D. Maslov, Z.I. Kolar, G.C. Krijger  More with less: Possible methods of producing 117mSn with high specific activity

10 th Congress of WNFMB, Cape Town South Africa, 18 – 23 September 2010

Published in World Journal of Nuclear Medicine – Volume 9, September 2010, S41

 

T Ebenhan, Z Szucs, K. Cimpeanu, D  Dudu J.R. Zeevaart. Production of 68Ge from natural Zink by cyclotron 1st World Congress on Gallium-68 and Peptide Receptor Radionuclide Therapy (PRRNT) THERANOSTICS – on the Way to Personalized Medicine, Zentralklinik Bad Berka, Germany – June 23-26, 2011.

Published in World Journal of Nuclear Medicine – Volume 10, June 2011, 73

 

T Ebenhan, N. Chadwick, T. Govender, H.G. Kruger, M. Sathekge, J.R. Zeevaart. Gallium-68 labelling of NOTA-peptide conjugates for imaging infection – especially tuberculosis. 1st World Congress on Gallium-68 and Peptide Receptor Radionuclide Therapy (PRRNT) THERANOSTICS – on the Way to Personalized Medicine, Zentralklinik Bad Berka, Germany – June 23-26, 2011.

Published in World Journal of Nuclear Medicine – Volume 10, June 2011, 86

 

S.M. Ferreira, A.M. Abrantes, L.F. Metello,  J.R. Zeevaart, W.K.A. Louw, I.C. Dormehl,  M.F. Botelho. 188Re-PEI-MP as a potential agent for metabolic radiotherapy. European Association of Nuclear Medicine, Birmingham, UK, 15-19 October 2011.

Published in Eur. J. Nucl. Med. Mol Imaging  38, suppl. 2, S213, 2011

 

B Kweto, DR Groot, J Suthiram, L Stassen, JR Zeevaart. The use of ammonium carbonate as lixiviant in uranium leaching.  ALTA 2012 conference on nickel/cobalt/copper, uranium & gold. 26 May- 2 June 2012, Perth, Australia

Published in Proceeding of Uranium sessions at ALTA 2012, ISBN: 978-0-9871262-4-5, p.139-149

 

T. Ebenhan T. Govender, G.H. Kruger, T. Pulker, V.Naidoo, J.R. Zeevaart and M. Sathekge. Synthesis of 68Ga-NOTA-UBI30-41 and in vivo Biodistribution in vervet Monkeys towards potential PET/CT Imaging of Infection. SNM 2012 annual meeting, 9-13 June 2012, Miami beach, Florida, USA. Published in J. Nucl. Med. 2012 vol 53, suppl 1, P1520,

 

Jansen, David R., Sepini, Lebogang C. Jarvis, Neil V. Zeevaart, Jan Rijn  A thermodynamic evaluation of 1,4,7,10-tetraazacyclododecane-1,4,7,10 tetra(methane-phosphonic acid) (DOTP) as a component of the bone-seeking radiopharmaceutical [177Lu]Lu(ΙII)-DOTP, towards establishing blood plasma model for  Lu(III). 20th International Symposium on Radiopharmaceutical Sciences 2013, IC Jeju, Korea, 12-17 May 2013

Published in J Label Compd Radiopharm 2013; 56: S439

 

Jansen, David R., Sepini, Lebogang C. Jarvis, Neil V. Zeevaart, Jan Rijn  Complexation studies of [177Lu]Lu(ΙII) with ethylenediaminetetra(methylene phosphonic acid) (EDTMP) as a potential agent for bone pain palliative radiotherapy. 20th International Symposium on Radiopharmaceutical Sciences 2013, IC Jeju, Korea, 12-17 May 2013

Published in J Label Compd Radiopharm 2013; 56: S440

 

Wagener J.M., Zinn C., Marjanovic-Painter B., Soni N., Perkins G., Sathekge M.M., Smith S.V, Zeevaart J.R., Production of high specific activity 195mPt-Cisplatinum at Necsa for pahse 0 clinical trials in healthy individuals, ANZSNM, Perth Australia, 11 – 15 April 2013

Published in Internal Medicine Journal. 2013; 43 (S1), 14-15

 

J.R. Zeevaart, Z. Szucs, S. Takacs, DR Jansen. Recoil and conversion electron implications to be taken into account in the design of therapeutic radiopharmaceuticals utilising in vivo generators. ANZSNM, Perth Australia, 11 – 15 April 2013

Published in Internal Medicine Journal. 2013; 43 (S1), 37

 

Thomas Ebenhan1,5, Jacobus D. Venter2, Daniel J. Goosen3, JanRijn Zeevaart4, Neil Jarvis5, Mike Sathekge1 NOTA conjugation to UB129-41 allows highly selective infection imaging with PET/CT:  A feasibility study in rabbits. World molecular Imaging congress, 2013, 18-21 September 2013, Savannah, USA

Published in Molecular Imaging and Biology 2013: 15, S1137-1138


 

Papers Refereed

 

10

 

Theses Refereed

 

7 MSc & 2 PhD

 

Editorship

 

Guest Editor, Journal of Radioanalytical and Nuclear Chemistry, 257, No.1, July 2003

 

Scientific committee

 

Chair and Member of 4ICI (4th International Conference on Isotopes) scientific advisory committee, Cape Town, March 2002

Member of 5ICI (5th International Conference on Isotopes) scientific advisory committee, Brussels, April 2005

Member of 6ICI (6th International Conference on Isotopes) scientific advisory committee, Seoul, May 2008